5th Nov 2020 16:32
Open Orphan PLC - contract research organisation & pharmaceutical services company - Subsidiary hVIVO signs GBP2.5 million contract with unnamed US biotech firm to conduct an influenza human challenge study.
Study is expected to start at hVIVO's clinic in east London in the second half of 2021, and be completed by the end of that year.
Current stock price: 26.50 pence
Year-to-date change: up sharply from 4.55p
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
ORPH.L